Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
CTD_human |
The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.
|
28472521 |
2018 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
BEFREE |
We confirmed the association between variants within genes that code nicotinic-acetylcholine receptors (-A3, -A5 and -B3), CYP2A6/B6 and tobacco dependence development in the Czech population.
|
28069549 |
2017 |
Tobacco Dependence
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Cox's proportional hazards models compared the risk of ICD-10 tobacco dependence acquisition (score 3+) for CYP2A6 and CYP2B6 metabolism groups.
|
26644138 |
2016 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
CTD_human |
Cox's proportional hazards models compared the risk of ICD-10 tobacco dependence acquisition (score 3+) for CYP2A6 and CYP2B6 metabolism groups.
|
26644138 |
2016 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
BEFREE |
No significant difference of tobacco dependence between normal and reduced metabolizers of CYP2A6 gene was found (FEM: SMD = 0.185, 95%CI = -0.001 to 0.371).
|
25683822 |
2015 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
CTD_human |
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
|
22569203 |
2012 |
Tobacco Dependence
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Conversion to TD and TD status were associated with the intensity of recent (that is, past 3-month) cigarette consumption (adjusted incidence rate ratio (aIRR) 1.63 (95% confidence interval (CI) 1.36 to 1.97) and adjusted prevalence odds ratio (aPOR) 1.35 (95% CI 1.23 to 2.48) per 100 cigarettes per month), slowest CYP2A6 activity (aIRR 4.19 (95% CI 1.38 to 12.76) and aPOR 2.30 (95% CI 1.29 to 4.09)), depression score (aIRR 1.61 (95% CI 1.17 to 2.21) and aPOR 1.47 (95% CI 1.22, 1.75) per 1-unit change).
|
16728750 |
2006 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
CTD_human |
Smoking cessation program and CYP2A6 polymorphism.
|
16720336 |
2006 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
BEFREE |
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
|
15564629 |
2004 |
Tobacco Dependence
|
0.380 |
Biomarker
|
disease |
CTD_human |
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
|
15564629 |
2004 |
Tobacco Dependence
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The clinical implications of CYP2A6 polymorphisms have been linked to a decreased risk of tobacco dependence, a decrease in number of cigarettes smoked and reduced risk of tobacco-related cancers.
|
12818518 |
2003 |
Tobacco Dependence
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Recent data have suggested that CYP2A6 genetic polymorphisms might play a role in tobacco dependence and consumption as well as in lung cancer risk.
|
11207029 |
2001 |
Tobacco Dependence
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence.
|
11054771 |
2000 |